Panacea Biotec is currently trading at Rs. 78.00, up by 0.75 points or 0.97% from its previous closing of Rs. 77.25 on the BSE.
The scrip opened at Rs. 78.50 and has touched a high and low of Rs. 79.50 and Rs. 77.55 respectively.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 199.45 on 26-Apr-2011 and a 52 week low of Rs. 70.00 on 30-Dec-2011.
Last one week high and low of the scrip stood at Rs. 86.00 and Rs. 77.00 respectively. The current market cap of the company is Rs. 521.00 crore.
The promoters holding in the company stood at 74.85% while Institutions and Non-Institutions held 3.18% and 21.97% respectively.
Panacea Biotec, India's leading vaccine manufacturer has launched Polprotec, an enhanced potency, inactivated poliovirus vaccine in Nigeria in collaboration with Emzor Pharma, Nigeria.
Further, Panacea Biotec and Emzor have together unveiled their joint planet Polio-Free mission statement to contribute towards achieving the goal of global polio eradication and to ensure that no child will ever again be paralyzed by WPV or Vaccine-Derived Polio Virus (VDPV). For this they will provide a complete portfolio of Oral Polio Vaccines (OPV), Inactivated Polio Vaccine (IPV) and IPV based combination vaccine at an affordable price.
Polprotec was launched by President of Pediatric Association of Nigeria (PAN) in PANCONF 2012. Over 200 pediatricians from all over Nigeria attended the conference.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |